Acasti Pharma Stock Cash And Equivalents
| ACSTDelisted Stock | USD 3.37 0.01 0.30% |
Acasti Pharma fundamentals help investors to digest information that contributes to Acasti Pharma's financial success or failures. It also enables traders to predict the movement of Acasti Stock. The fundamental analysis module provides a way to measure Acasti Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acasti Pharma stock.
Acasti |
Acasti Pharma Company Cash And Equivalents Analysis
Acasti Pharma's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Acasti Pharma Cash And Equivalents | 38.39 M |
Most of Acasti Pharma's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acasti Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Acasti Pharma has 38.39 M in Cash And Equivalents. This is 95.32% lower than that of the Pharmaceuticals sector and 91.41% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 98.58% higher than that of the company.
Acasti Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acasti Pharma's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acasti Pharma could also be used in its relative valuation, which is a method of valuing Acasti Pharma by comparing valuation metrics of similar companies.Acasti Pharma is currently under evaluation in cash and equivalents category among its peers.
Acasti Fundamentals
| Return On Equity | -0.19 | |||
| Return On Asset | -0.12 | |||
| Current Valuation | 11.17 M | |||
| Shares Outstanding | 10.14 M | |||
| Shares Owned By Insiders | 38.39 % | |||
| Shares Owned By Institutions | 21.22 % | |||
| Number Of Shares Shorted | 154.19 K | |||
| Price To Earning | 15.34 X | |||
| Price To Book | 0.58 X | |||
| Price To Sales | 208.39 X | |||
| Gross Profit | 120 K | |||
| EBITDA | (11.3 M) | |||
| Net Income | (12.85 M) | |||
| Cash And Equivalents | 38.39 M | |||
| Cash Per Share | 0.86 X | |||
| Total Debt | 11.56 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 11.13 X | |||
| Book Value Per Share | 5.86 X | |||
| Cash Flow From Operations | (12.33 M) | |||
| Short Ratio | 3.84 X | |||
| Earnings Per Share | (1.43) X | |||
| Target Price | 7.97 | |||
| Beta | 1.52 | |||
| Market Capitalization | 36.5 M | |||
| Total Asset | 73.3 M | |||
| Retained Earnings | (211.12 M) | |||
| Working Capital | 22.33 M | |||
| Current Asset | 11.33 M | |||
| Current Liabilities | 1.14 M | |||
| Net Asset | 73.3 M |
About Acasti Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acasti Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acasti Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acasti Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Acasti Stock
If you are still planning to invest in Acasti Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acasti Pharma's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |